http://www.infozine.com/news/stories...iew/sid/18283/

Copaxone may slow axonal damage and tissue damage and may even lead to tissue recovery.

Pantos,

Hoping not to sound negative on the info you posted, it is not surprising to hear Dr. O. Khan heading up studies that take existing data on Copaxone and turning it into promotional releases on the drug. Teva, as well as the other MS drug producing pharmas, are in quite the marketing battle with Biogen/Elan now that Tysabri is back in the picture.

It is quite evident that Dr. Khan is getting financially compensated for his info on Copaxone. Do a search on Google and you will see his name associated with other promotional work for Teva. This is but one example (please note it does not refer to your post but to previous work done by Khan for Teva)

"Initial reports on Wednesday indicated that the research was funded by Wayne State University, in Detroit. However, Thursday, the Wayne State researcher, Omar Khan, said that, while the study itself was independent, he received an "unrestricted educational grant" to publicize the findings from the Teva Marion Partnership."

Copaxone has had some open label trial data published in the past 6 months and we hear the word "may" being used a lot to interpret findings which suggest Copaxone is better than the other CRAB drugs. The big four MS Pharmas are spending a lot of money in their marketing wars in order to protect their share of this multi-million dollar business. It's too bad that this money isn't being spent on more efforts to find the cause for MS as opposed to making more money for the companies who are in the drug selling business.

Harry